Enanta Pharmaceuticals (NASDAQ:ENTA) is scheduled to post its quarterly earnings results after the market closes on Thursday, May 6th. Analysts expect Enanta Pharmaceuticals to post earnings of ($0.94) per share for the quarter. Persons interested in registering for the company’s earnings conference call can do so using this link.

Enanta Pharmaceuticals (NASDAQ:ENTA) last announced its earnings results on Sunday, February 7th. The biotechnology company reported ($0.41) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.74) by $0.33. Enanta Pharmaceuticals had a negative return on equity of 3.75% and a negative net margin of 29.53%. The business had revenue of $31.74 million for the quarter, compared to analysts’ expectations of $27.73 million. During the same period in the prior year, the business posted $0.65 earnings per share. The firm’s revenue was down 39.6% on a year-over-year basis. On average, analysts expect Enanta Pharmaceuticals to post $-4 EPS for the current fiscal year and $-6 EPS for the next fiscal year.

Enanta Pharmaceuticals stock traded down $0.23 during mid-day trading on Tuesday, hitting $52.88. 134 shares of the stock were exchanged, compared to its average volume of 143,301. The firm’s fifty day simple moving average is $50.53 and its two-hundred day simple moving average is $47.41. Enanta Pharmaceuticals has a 12 month low of $40.32 and a 12 month high of $58.59. The stock has a market capitalization of $1.07 billion, a price-to-earnings ratio of -29.18 and a beta of 0.54.

Several research firms recently issued reports on ENTA. Zacks Investment Research cut shares of Enanta Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Tuesday, April 27th. JPMorgan Chase & Co. upgraded Enanta Pharmaceuticals from an “underweight” rating to a “neutral” rating and upped their target price for the company from $44.00 to $55.00 in a research report on Friday, January 29th. Finally, Royal Bank of Canada lifted their target price on Enanta Pharmaceuticals from $47.00 to $53.00 and gave the stock a “sector perform” rating in a report on Tuesday, February 9th. Two analysts have rated the stock with a sell rating, three have assigned a hold rating and three have assigned a buy rating to the company. Enanta Pharmaceuticals presently has a consensus rating of “Hold” and an average price target of $64.88.

About Enanta Pharmaceuticals

Enanta Pharmaceuticals, Inc, a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, non-alcoholic steatohepatitis, SARS-CoV-2, human metapneumovirus, and hepatitis B virus.

See Also: What is required to own or exchange cryptocurrency?

Earnings History for Enanta Pharmaceuticals (NASDAQ:ENTA)

Receive News & Ratings for Enanta Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enanta Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.